✦ LIBER ✦

Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinomas of the head and neck

✍ Scribed by Peter J. F. Snijders; Andrea G. M. Scholes; C. Anthony Hart; Andrew S. Jones; E. David Vaughan; Julia A. Woolgar; Chris J. L. M. Meijer; Jan M. M. Walboomers; John K. Field

Publisher: John Wiley and Sons
Year: 1996
Tongue: French
Weight: 671 KB
Volume: 66
Category: Article
ISSN: 0020-7136
DOI: 10.1002/(sici)1097-0215(19960516)66:4<464::aid-ijc9>3.0.co;2-u

No coin nor oath required. For personal study only.

✦ Synopsis

The prevalence of mucosotropic human papillomavirus (HPV) DNA in 63 squamous-cell carcinomas (SCC) from different anatomic sites in the head and neck was determined by general primer-mediated polymerase chain reaction (GP-PCR). HPV DNA was detected in 20.6% of SCC. Additional type-specific PCR for HPV 6, I I, 16, 18, 31 and 33 demonstrated the presence of HPV I6 alone in these carcinomas. HPV I 6 was also detected in normal epithelium from the resection margins of the majority of HPV-positive SCC. HPV status did not correlate with tumour site, whether primary or recurrent, TNM stage, metastases, degree of differentiation, smoking or alcohol history, fate or survival.

📜 SIMILAR VOLUMES

Prevalence and physical status of human

Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck

✍ Walter J. Koskinen; Ren Wei Chen; Ilmo Leivo; Antti Mäkitie; Leif Bäck; Risto Ko 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 168 KB 👁 2 views

## Abstract Fresh‐frozen biopsies were obtained from 61 patients at diagnosis of squamous cell carcinoma of the head and neck (HNSCC) for study of the prevalence and physical status of human papillomavirus (HPV) DNA. The frequency of HPV DNA and genotypes were determined by SPF10 PCR screening with

Biological evidence that human papilloma

Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas

✍ Viola M.M. van Houten; Peter J.F. Snijders; Michiel W.M. van den Brekel; J. Alai 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 66 KB

High-risk human papillomaviruses (HPVs) have been proposed to be associated with a subset of head and neck cancers (HNSCCs). However, clear biological evidence linking HPV-mediated oncogenesis to the development of HNSCC is hardly available. An important biological mechanism underlying HPV-mediated

Histologic differentiation and chemosens

Histologic differentiation and chemosensitivity of human head and neck squamous cell carcinomas

✍ Dr. Tadashi Nakashima; Drs. Yoshihiko Maehara; Shunji Kohnoe; Itsuroh Hayashi; Y 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB 👁 2 views

## Abstract The chemosensitivities of 42 human head and neck squamous cell carcinomas were examined using the in vitro succinate dehydrogenase inhibition (SDI) test. The tumor tissues obtained at surgery or biopsy were exposed to five different antitumor drugs: adriamycin (ADM), cisplatin (CDDP), c

Growth of human head and neck squamous c

Growth of human head and neck squamous cell carcinoma stem cells in agarose

✍ Leonard J. Schiff; Martin A. Shugar 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 671 KB

Loss of heterozygosity studies in squamo

Loss of heterozygosity studies in squamous cell carcinomas of the head and neck

✍ David T. Ransom; J. Helen Leonard; John H. Kearsley; Gavin R. Turbett; Kathy Hee 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 800 KB

Background. Loss of heterozygosity (LOH) studies have been pivotal in identifying tumor suppressor genes involved in the pathogenesis of a number of cancers. In squamous cell carcinomas of the head and neck region (SCCHN), LOH studies using the Southern blot technique are scarce. Methods. SCCHNs we

Targeted therapies in squamous cell carc

Targeted therapies in squamous cell carcinoma of the head and neck

✍ Kathryn A. Gold; Ho-Young Lee; Edward S. Kim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 3 views

## Abstract Head and neck cancer is a challenging disease that is expected to account for greater than 500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy and radiation for head and neck cancer, and the prognosis for patients with recurrent and/or metastatic disease r